Intrepid Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• CB-03-01 · Dermatology
  CB-03-01 is a selective androgen receptor modulator (SARM) that inhibits 5-alpha reductase to reduce DHT-driven androgenetic alopecia.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Intrepid Therapeutics, Inc. portfolio CI brief
• Intrepid Therapeutics, Inc. pipeline updates RSS